Gastric Cancer (GC)NCT07403916
Influence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric Cancer
An observational study of Gastric Cancer (GC) and Next-generation Sequencing, run by P. Herzen Moscow Oncology Research Institute at 1 site in Russia.
Trial summary
Next-generation sequencing (NGS) and biomarkers play a key role in the diagnosis and personalized therapy of gastric cancer. These technologies provide a deep understanding of the molecular basis of the disease. NGS allows simultaneous analysis of multiple genes, identifying mutations and changes in their expression. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gastric Cancer (GC), Next-generation Sequencing, Molecular Analysis
- What is being tested?
- Next-generation sequencing
- How many people
- 90 participants
- Where
- 1 siteRussia
- Study dates
- 10 Jan 2020to 1 Jun 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All consecutive patients with clinically documented primary gastric cancer undergoing elective surgery with curative intent
Who may be able to join
- Patients with histologically confirmed diagnosis of gastric cancer
- The resectable stage of the disease (I-III)
- Availability of complete clinical data, including age, gender, stage of the disease, concomitant diseases, treatment tactics and outcomes
- Indicated radical surgical intervention both at the first stage and after neoadjuvant chemotherapy
- Localization of the tumor: Type II-III cardioesophageal junction according to Siewert, upper, middle and lower third of the body, angle of the stomach or antrum (U,M,L-level according to the Japanese classification)
Who cannot join
- The presence of metastases in distant organs at the time of diagnosis
- Primary-multiple tumors
- Diagnostic and palliative surgery
- Incomplete clinical data
- Pregnancy
Trial locations and contacts
1 site in 1 country.
About this study
Next-generation sequencing (NGS) and biomarkers play a key role in the diagnosis and personalized therapy of gastric cancer. These technologies provide a deep understanding of the molecular basis of the disease.
NGS allows simultaneous analysis of multiple genes, identifying mutations and changes in their expression. In case of stomach cancer, this makes it possible to identify specific mutations to determine prognosis and treatment choice, study the genomic profiles of patients to find targets for targeted and immunotherapy.
Read more
The use of NGS and biomarkers allows the development of individualized treatment regimens, increasing effectiveness and reducing side effects. Biomarker analysis also helps to track the progression of the disease and identify patients at high risk of relapse.
The study of molecular genetic markers in tumor tissues, as well as the influence of genetic and age-related factors, is an important scientific and clinical task. Solving this problem will create a personalized approach to patient management.
This work examines the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on the analysis of surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations in various age groups.
Read the detailed description
Gastric cancer remains one of the most important malignant tumors with significant geographical and regional differences in prevalence. Despite the decrease in the incidence of gastric cancer in advanced economies, this pathology still ranks fifth among patients with malignant neoplasms. As for cancer mortality rates, stomach cancer ranks third. Stomach cancer continues to be one of the most significant oncological diseases in the world, ranking fifth in terms of prevalence according to global statistics from GLOBOCAN 2022.
Modern medicine uses diagnostic technology - Next-generation sequencing (NGS), and biomarkers play an important role in the diagnosis, prognosis, and treatment of stomach cancer. These technologies provide a deep understanding of the molecular mechanisms underlying the disease and open up new possibilities for personalized therapy. NGS allows simultaneous analysis of multiple genes and detection of mutations, changes in gene expression and other genetic features. In the context of stomach cancer, next-generation sequencing allows for identification of mutations: Detection of specific mutations associated with stomach cancer can help determine prognosis and select appropriate treatment, study of the genomic profiles of patients: To identify potential targets for therapy, including immune and targeted drugs.
With the help of NGS and biomarkers, doctors can develop individualized treatment regimens for different age groups, which increases the effectiveness of therapy and reduces side effects. Biomarker analysis allows you to track the progression of cancer and identify patients with a high risk of recurrence. The study and determination of molecular genetic markers in tumor tissues, as well as the analysis of genetic and age-related factors influencing the development of gastric cancer, is an important scientific and clinical task. Solving this problem may allow us to develop a personalized approach to patient management.
This scientific paper will address the issue of the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations of various age groups in resectable gastric cancer.
- Being tested
- Next-generation sequencing
- Keywords
- Gastric cancer surgery, Next-generation sequencing, Gastric cancer treatment
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Next-generation sequencingDiagnostic test
Technology for determining the sequence of DNA to study genetic variation associated with diseases or other biological phenomena
| Study group | Role | What they receive |
|---|---|---|
| Уoung-adult age group | age 18-44 yr. Receives: Diagnostic Test: Next-generation sequencing | |
| Middle-aged group | age 45-59 yr. Receives: Diagnostic Test: Next-generation sequencing | |
| Eldery age group | age 60-74 yr. Receives: Diagnostic Test: Next-generation sequencing | |
| Senior age group | age > 75 yr. Receives: Diagnostic Test: Next-generation sequencing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Measured: 3 months
Secondary outcomes (3)
Mutational burden and genomic instability features assessed by NGS
Measured: 3 months
Spectrum of somatic mutations identified by NGS
Measured: 3 months
Disease free survival
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2026
- Study start10 Jan 2020
- Primary completion31 Dec 2025
- Study completion1 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric Cancer (GC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- P. Herzen Moscow Oncology Research Institute
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Vakhtang Begiashvili, P. Herzen Moscow Oncology Research Institute
- Investigators
- Andrey Ryabov, MD, PhD, Study director, P.Herzen Moscow Oncological Research InstituteVakhtang Begiashvili, PhD student, Principal investigator, P.Herzen Moscow Oncological Research InstituteVladimir Khomyakov, MD, PhD, Principal investigator, P.Herzen Moscow Oncological Research InstituteNadezhda Volchenko, MD, PhD, Principal investigator, P.Herzen Moscow Oncological Research InstituteShatalov Peter, PhD, Principal investigator, P.Herzen Moscow Oncological Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07403916
- Sponsor's protocol ID
- 129
- Status last verified
- Feb 2026
- First submitted
- 4 Feb 2026
- Last updated
- 11 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Influence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric Cancer
- ClinicalTrials.gov ID
- NCT07403916
- Acronym / sponsor ID
- 129
- Keywords
- Gastric cancer surgery, Next-generation sequencing, Gastric cancer treatment
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 90 participants (actual)
- Lead sponsor
- P. Herzen Moscow Oncology Research InstituteOther government
- Study start
- 10 Jan 2020 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 1 Jun 2026 (estimated)
- First posted
- 11 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Next-generation sequencing (NGS) and biomarkers play a key role in the diagnosis and personalized therapy of gastric cancer. These technologies provide a deep understanding of the molecular basis of the disease.
NGS allows simultaneous analysis of multiple genes, identifying mutations and changes in their expression. In case of stomach cancer, this makes it possible to identify specific mutations to determine prognosis and treatment choice, study the genomic profiles of patients to find targets for targeted and immunotherapy.
The use of NGS and biomarkers allows the development of individualized treatment regimens, increasing effectiveness and reducing side effects. Biomarker analysis also helps to track the progression of the disease and identify patients at high risk of relapse.
The study of molecular genetic markers in tumor tissues, as well as the influence of genetic and age-related factors, is an important scientific and clinical task. Solving this problem will create a personalized approach to patient management.
This work examines the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on the analysis of surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations in various age groups.
Detailed description
Gastric cancer remains one of the most important malignant tumors with significant geographical and regional differences in prevalence. Despite the decrease in the incidence of gastric cancer in advanced economies, this pathology still ranks fifth among patients with malignant neoplasms. As for cancer mortality rates, stomach cancer ranks third. Stomach cancer continues to be one of the most significant oncological diseases in the world, ranking fifth in terms of prevalence according to global statistics from GLOBOCAN 2022.
Modern medicine uses diagnostic technology - Next-generation sequencing (NGS), and biomarkers play an important role in the diagnosis, prognosis, and treatment of stomach cancer. These technologies provide a deep understanding of the molecular mechanisms underlying the disease and open up new possibilities for personalized therapy. NGS allows simultaneous analysis of multiple genes and detection of mutations, changes in gene expression and other genetic features. In the context of stomach cancer, next-generation sequencing allows for identification of mutations: Detection of specific mutations associated with stomach cancer can help determine prognosis and select appropriate treatment, study of the genomic profiles of patients: To identify potential targets for therapy, including immune and targeted drugs.
With the help of NGS and biomarkers, doctors can develop individualized treatment regimens for different age groups, which increases the effectiveness of therapy and reduces side effects. Biomarker analysis allows you to track the progression of cancer and identify patients with a high risk of recurrence. The study and determination of molecular genetic markers in tumor tissues, as well as the analysis of genetic and age-related factors influencing the development of gastric cancer, is an important scientific and clinical task. Solving this problem may allow us to develop a personalized approach to patient management.
This scientific paper will address the issue of the influence of age on the choice of treatment tactics and prognosis in patients with resectable gastric cancer. The main focus is on surgical, chemotherapeutic, topographic, pathomorphological, and molecular genetic correlations of various age groups in resectable gastric cancer.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Уoung-adult age group | – | Diagnostic Test: Next-generation sequencingage 18-44 yr. |
| Middle-aged group | – | Diagnostic Test: Next-generation sequencingage 45-59 yr. |
| Eldery age group | – | Diagnostic Test: Next-generation sequencingage 60-74 yr. |
| Senior age group | – | Diagnostic Test: Next-generation sequencingage > 75 yr. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All consecutive patients with clinically documented primary gastric cancer undergoing elective surgery with curative intent
Key inclusion criteria (5 listed)
- Patients with histologically confirmed diagnosis of gastric cancer
- The resectable stage of the disease (I-III)
- Availability of complete clinical data, including age, gender, stage of the disease, concomitant diseases, treatment tactics and outcomes
- Indicated radical surgical intervention both at the first stage and after neoadjuvant chemotherapy
- Localization of the tumor: Type II-III cardioesophageal junction according to Siewert, upper, middle and lower third of the body, angle of the stomach or antrum (U,M,L-level according to the Japanese classification)
Key exclusion criteria (5 listed)
- The presence of metastases in distant organs at the time of diagnosis
- Primary-multiple tumors
- Diagnostic and palliative surgery
- Incomplete clinical data
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Next-generation sequencingTechnology for determining the sequence of DNA to study genetic variation associated with diseases or other biological phenomena | Diagnostic test | Eldery age group, Middle-aged group, Senior age group, Уoung-adult age group |
Primary outcome
Overall survival
Time frame: 3 months
3 secondary outcomes
Mutational burden and genomic instability features assessed by NGS
Time frame: 3 months
Spectrum of somatic mutations identified by NGS
Time frame: 3 months
Disease free survival
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Gastric Cancer (GC)
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Recruiting
TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
Gastric Cancer (GC), Stomach Neoplasms
Not yet recruitingPhase 2
Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
RecruitingPhase 2
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Gastroesophageal Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andrey Ryabov, MD, PhD study director
P.Herzen Moscow Oncological Research Institute
Vakhtang Begiashvili, PhD student principal investigator
P.Herzen Moscow Oncological Research Institute
Vladimir Khomyakov, MD, PhD principal investigator
P.Herzen Moscow Oncological Research Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastric Cancer (GC) and Next-generation Sequencing, run by P. Herzen Moscow Oncology Research Institute at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 11 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2026.